Qyuns Therapeutics Co., Ltd. announced that on May 9, 2024, QX013N, a humanized IgG1 monoclonal antibody independently developed by the Company, has received the Investigational New Drug (IND) clearance from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China (acceptance number: CXSL2400165) for treatment of chronic spontaneous urticaria ("CSU"). QX013N specifically binds to c-kit to inhibit the differentiation, maturation, survival, proliferation and degranulation of mast cells, resulting in the reduction and depletion of mast cells for treatment of mast cell-driven diseases such as CSU. The Company continues to strengthen its presence in the field of autoimmune and allergic diseases.

The approval of QX013N in CSU indicates that the Company has established a comprehensive presence in the four major dermatological indications (psoriasis, atopic dermatitis, prurigo nodularis and CSU), further consolidating its competitive advantages in dermatology. In response to the unmet medical needs of tens of millions of dermatologic patients in China, the Company will strive to benefit patients from a wider range of treatment options by advancing clinical trials in a more efficient manner.